



IBA postpones its share premiums reimbursement

Louvain-la-Neuve, Belgium, September 25, 2012

During the Extraordinary General Assembly held yesterday, which had to decide upon the reimbursement of share premiums, the shareholders followed the recommendation of the Board of Directors and voted to postpone the decision.

Indeed, as mentioned in the press release on the first half 2012 results published end of August, the sale of the minority stake in Pharmalogic (IBA Molecular business in Canada) was postponed. In addition, the litigation on the Essen file is on the right track towards resolution but not close enough to a conclusion to give IBA a clear picture on its consequences.

The Board considered that all the elements which laid to the postponement during the assembly of July have not progressed enough since. Therefore the Board recommended to postpone the decision again.

The majority of shareholders followed the recommendations of the Board and mandated the Board to convene an Extraordinary General Assembly later.

About IBA

IBA (Ion Beam Applications S.A.), is the global high-tech leader in next generation radiation therapy and diagnostics of cancer. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. Further information can be found at: www.iba-worldwide.com

For more information, please contact:

IBA

Jean-Marc Bothy

Chief Financial Officer

+32 10475890

investorrelations@iba-group.com

For media and investor enquiries about IBA:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire

Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com